Results - Announcements
Medicamen Biotech Ltd share price gained 4.59% to Rs 282.7 after the company's net profit soared by 122.70% to Rs 4.12 crore, while revenue from operations increased 14.47% to Rs 54.83 crore in Q2FY27 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.83 lakh crore, gaining 6.63%. It has marginally improved by 2.52% over last one week and moved up slightly by 5.98% in last one month while the market capitalization of Medicamen Biotech Ltd has improved by 2.65% and 21.76% in the same period respectively.
Profit before tax (PBT) of Medicamen Biotech Ltd stood at Rs 5.12 crore in Q2 FY27, jumping 91.04% year-on-year, and rallying 99.22% quarter-on-quarter. EBITDA came in at Rs 9 crore, expanding by 81.21% YoY and surging by 150.14% sequentially.
Total expenses grew marginally by 5.86% to Rs 48.02 crore in Q2FY27 over Q2FY26. During the quarter, cost of materials consumed stood at Rs 11.07 crore, registering a fall of 51.04% YoY, while employee benefits expense was at Rs 9.65 crore, inching up 3.65% YoY.
For FY26, revenue from operations surged 21.67% to Rs 197.77 crore, while net profit saw a strong growth of 49.39% to Rs 9.8 crore, compared to previous FY. EBITDA jumped by 677% to Rs 16.48 crore, and PBT witnessed a strong rise of 21.26% to Rs 11.98 crore compared to previous FY.
The company's consolidated net cash flow from operating activities stood at Rs 33.17 crore in FY26, as against Rs 7.19 crore in FY25.
Medicamen Biotech Ltd nosedived by 33.68% in last one year, underperforming the benchmark BSE Sensex which has eased by 3.03% during the same period.